Core Viewpoint - Yirui Technology reported a steady growth in revenue and net profit for the first half of 2025, with a focus on global market expansion and supply chain digitalization [1][2]. Financial Performance - In the first half of 2025, Yirui Technology achieved revenue of 1.067 billion yuan, a year-on-year increase of 3.94% - The net profit attributable to the parent company was 334 million yuan, reflecting a year-on-year growth of 8.82% [2]. R&D Investment - The company invested 154 million yuan in R&D, accounting for 14.46% of its revenue - Yirui Technology added 70 new intellectual property rights, including 32 invention patents - Key projects include the development of digital X-ray detector technologies and the establishment of an innovation base [3]. Global Market Expansion - Yirui Technology participated in international exhibitions such as CMEF, ECR, and Arab Health to promote new products globally - The company established sales and service platforms in the US, Germany, and South Korea, and expanded teams in emerging markets like Pakistan and Brazil - It became a major supplier of dental CBCT detectors in South Korea and benefited from domestic medical imaging projects [4]. Supply Chain Digitalization - To enhance delivery capabilities, Yirui Technology is advancing automation and digital transformation in production - The company has formed a global layout of "1 headquarters + 6 bases," including facilities in Haining, Taicang, Cleveland, and a new base in Hefei [5].

Group 1 - The core viewpoint of the news highlights the performance and valuation of Yirui Technology, which closed at 110.0 yuan, marking a 1.84% increase, with a rolling PE ratio of 44.74, the lowest in 45 days, and a total market capitalization of 22.024 billion yuan [1] - Yirui Technology ranks 81st in the medical device industry, which has an average PE ratio of 59.49 and a median of 40.19 [1] - As of June 30, 2025, Yirui Technology had 6,990 shareholders, an increase of 1,245 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Yirui Technology's main business includes the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combined ray sources, and tubes [1] - The latest financial results for the first half of 2025 show that the company achieved a revenue of 1.067 billion yuan, a year-on-year increase of 3.94%, and a net profit of 335 million yuan, a year-on-year increase of 8.82%, with a gross profit margin of 52.97% [1] - The PE ratios of other companies in the medical device industry vary, with the highest being 20.67 for Antu Biology and the lowest being 11.65 for Jiuan Medical [2]

九州一轨:李秀清辞去财务总监及财务负责人职务 宏微科技:聘任王巧巧担任公司财务总监 天成自控:徐华月辞去公司财务总监职务 截至发稿，奕瑞科技市值为191亿元。 延伸阅读： 每经AI快讯，奕瑞科技（SH 688301）8月15日晚间发布公告称，奕瑞电子科技集团股份有限公司董事 会于近日收到公司财务总监赵凯先生的辞职报告，赵凯先生因个人原因申请辞去公司财务总监职务，辞 职后不再担任公司任何职务。为确保财务管理工作的顺利开展，经公司总经理提名，并经公司董事会提 名委员会和审计委员会资格审查通过，公司董事会同意聘任蒋燕女士为公司财务总监。 2024年1至12月份，奕瑞科技的营业收入构成为：数字化X线探测器占比93.53%，其他业务占比6.47%。 ...

证券代码：688301 证券简称：奕瑞科技 公告编号：2025-057 转债代码：118025 转债简称：奕瑞转债 奕瑞电子科技集团股份有限公司 关于使用自有资金支付募投项目所需资金并以募集 资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日 分别召开第三届董事会第十七次会议、第三届监事会第十四次会议，审议通过了 《关于使用自有资金支付募投项目所需资金并以募集资金等额置换的议案》，同 意公司在募集资金投资项目（以下简称"募投项目"）实施期间，根据实际情况 先行使用自有资金支付募投项目所需资金，在履行内部相关审批程序后以募集资 金等额置换，该部分等额置换资金视同募投项目已使用资金。公司监事会发表了 明确的同意意见，保荐中国国际金融股份有限公司对本事项出具了明确的核查意 见，现将具体情况公告如下： 予以确认。公司对上述募集资金进行了专户存储管理。 二、募集资金投资项目情况 根据《上海奕瑞光电子科技股份有限公司向不特定对象发行可转 ...

Core Viewpoint - The company plans to utilize up to RMB 460 million of temporarily idle raised funds for cash management, focusing on low-risk, high-liquidity principal-protected products to enhance fund efficiency and maximize shareholder returns [1][9][11]. Fundraising Overview - The company raised a total of RMB 2,176.72 million from its initial public offering (IPO) by issuing 18.2 million shares at RMB 119.60 each, with a net amount of RMB 2,077.16 million after deducting related expenses [3]. - The company also issued convertible bonds totaling RMB 1,435.01 million, with a net amount of RMB 1,421.31 million after expenses [4]. Cash Management Plan - The company intends to invest the idle funds in safe, liquid, low-risk principal-protected products, including but not limited to wealth management products, structured deposits, fixed deposits, large certificates of deposit, and seven-day notice deposits [7][9]. - The investment will be executed within a maximum period of 12 months from the board's approval date, allowing for rolling use of the funds [7][9]. Approval Process - The board and supervisory committee approved the cash management plan on August 15, 2025, with no need for shareholder meeting approval [2][8][12]. - The supervisory committee and the sponsor institution provided clear consent and no objections to the plan [2][12]. Impact on Operations - The cash management strategy is designed to ensure that the investment projects funded by the raised capital are not affected, maintaining the progress of the company's core business operations [9][11]. - The company aims to enhance the efficiency of fund usage and generate additional returns without altering the original fundraising purposes [10][11].

Core Business Expansion and Competitiveness Enhancement - The company is a digital X-ray core component and comprehensive solution supplier, focusing on R&D, production, sales, and services of digital X-ray detectors, high-voltage generators, and other core components [1] - The company has established a global layout with six production bases, including new facilities in Haining, Taicang, and Cleveland, enhancing its competitive edge [1] - In the first half of 2025, overseas revenue reached 366 million yuan, accounting for approximately 34% of total revenue, indicating a continuous increase in overseas business [1] Investment in New Projects - The company plans to invest up to 1.8 billion yuan in a silicon-based OLED microdisplay backplane production project, which will add a capacity of 5,000 units per month [2] - This investment is expected to enhance the company's technological innovation and strengthen its core competitiveness [2] R&D Innovation and High-Quality Development - The company invested 154.24 million yuan in R&D, representing 14.46% of its revenue, and registered 70 new IPs, including 32 invention patents [2] - Ongoing projects include the development of key technologies for digital X-ray detectors and the establishment of an innovation base [2][3] Governance and Operational Standards - The company has established a governance structure with clear responsibilities among the shareholders' meeting, board of directors, supervisory board, and management [4] - The company held multiple board meetings and complied with legal and regulatory requirements for governance [5] Shareholder Returns and Value Sharing - In June 2025, the company completed its 2024 annual equity distribution, distributing cash dividends of 10 yuan per 10 shares and a stock bonus of 4 shares per 10 shares, totaling 142.89 million yuan in cash dividends [6] ESG Commitment and Sustainable Development - The company integrates ESG principles into its strategy and operations, focusing on innovation and quality management to contribute to human health [7] - A report detailing the company's practices in environmental protection and social responsibility is available on the Shanghai Stock Exchange website [7] Future Plans - The company will continue to focus on digital X-ray core components and solutions, enhance governance structures, and improve risk management to achieve high-quality development [8]

中国国际金融股份有限公司 关于奕瑞电子科技集团股份有限公司使用自有资金支付募投项目 所需资金并以募集资金等额置换的核查意见 中国国际金融股份有限公司（以下简称"保荐机构"）作为奕瑞电子科技集团股份有 限公司（以下简称"奕瑞科技"或"公司"）的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法 规、部门规章及业务规则的要求，对奕瑞电子科技集团股份有限公司本次使用暂时闲置 募集资金进行现金管理的事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 经中国证监会《关于同意上海奕瑞光电子科技股份有限公司向不特定对象发行可转 债注册的批复》（证监许可[2022]2167 号）同意注册，公司向不特定对象共计发行 债募集资金总额为人民币 143,501.00 万元；扣除发行费用（不含增值税）人民币 1,369.65 万元后，募集资金净额为人民币 142,131.35 万元，上述资金已全部到位，经立信会计师 事务所（特殊普通合伙）审验并于 2022 年 10 月 28 ...

奕瑞科技（SH 688301，收盘价：95.35元）8月15日晚间发布公告称，奕瑞电子科技集团股份有限公司 董事会于近日收到公司财务总监赵凯先生的辞职报告，赵凯先生因个人原因申请辞去公司财务总监职 务，辞职后不再担任公司任何职务。为确保财务管理工作的顺利开展，经公司总经理提名，并经公司董 事会提名委员会和审计委员会资格审查通过，公司董事会同意聘任蒋燕女士为公司财务总监。 （文章来源：每日经济新闻） 2024年1至12月份，奕瑞科技的营业收入构成为：数字化X线探测器占比93.53%，其他业务占比6.47%。 ...

Core Viewpoint - Tianjin Sequoia and Beijing Sequoia plan to reduce their holdings in Yirui Technology by up to 4.0044 million shares, representing no more than 2% of the total shares, due to their own funding needs [1][2] Group 1: Shareholding and Reduction - The total amount from the maximum reduction is approximately 351 million yuan, based on the closing price of 87.99 yuan per share on the announcement date [1] - As of the announcement date, Tianjin Sequoia and Beijing Sequoia hold 11.7859 million shares and 5.5473 million shares of Yirui Technology, accounting for 5.89% and 2.77% of the total share capital, respectively [2] - The Sequoia group has been invested in Yirui Technology for thirteen years, participating in A and B round financing in 2012 and 2014 [1] Group 2: Historical Performance and Market Trends - Yirui Technology's stock price has been weak, with a decline of over 10% year-to-date, and the stock price was reported at 85.3 yuan per share, with a total market value of approximately 17.08 billion yuan [2] - The company’s revenue for 2022 to 2024 is reported as 1.549 billion yuan, 1.864 billion yuan, and 1.831 billion yuan, while the net profit attributable to shareholders is 641 million yuan, 607 million yuan, and 465 million yuan, respectively [2] - In the first quarter of 2025, Yirui Technology's revenue was 482 million yuan, showing a year-on-year decline of 1.92%, while the net profit attributable to shareholders was 143 million yuan, reflecting a year-on-year growth of 2.74% [2]

Group 1 - The core point of the article is that Sequoia Capital has initiated a share reduction plan for Yirui Technology, which is known as the "first stock of digital X-ray detectors" [1][2] - Sequoia Capital's Tianjin and Beijing branches currently hold a combined 17.33 million shares of Yirui Technology, representing 8.66% of the total share capital [1] - The planned reduction involves selling up to 4.0044 million shares, which is no more than 2% of the total share capital, potentially generating approximately 350 million yuan based on the current share price [1][2] Group 2 - Yirui Technology is a supplier of digital X-ray core components and comprehensive solutions, with applications in medical, dental, radiotherapy, veterinary, and industrial fields [2] - The company's performance has been under pressure, with a revenue decline of 1.74% year-on-year to 1.831 billion yuan in 2024, and a net profit drop of 25.84% to 439 million yuan [2] - In the first quarter of 2025, Yirui Technology reported a revenue of 482 million yuan, down 1.92% year-on-year, and a net profit of 141 million yuan, down 9.19% year-on-year [2]